Challenges in identifying cancer genes by analysis of exome sequencing data

Nature Communications

Volumn 7, Issue , 2016, Pages

  Hofree, Matan ^a,b,c   Carter, Hannah ^b,c,d   Kreisberg, Jason F ^a,c   Bandyopadhyay, Sourav ^e   Mischel, Paul S ^f   Friend, Stephen ^g   Ideker, Trey ^a,b,c,d  

^a La Jolla and San Francisco   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SAGE BIONETWORKS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SHORT HAIRPIN RNA;

CANCER; GENE EXPRESSION; GENETIC ANALYSIS; MOLECULAR ANALYSIS; MUTATION; TUMOR;

ARTICLE; CONTROLLED STUDY; EXOME; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; MUTATIONAL LOAD; NEOPLASM; SAMPLE SIZE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR GENE; GENETIC DATABASE; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PROCEDURES;

DATABASES, GENETIC; EXOME; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; MUTATION RATE; NEOPLASMS;

EID: 84978732015     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12096     Document Type: Article

References (54)

1. Pleasance, E. D. et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196 (2010).
2. Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
3. Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993-998 (2010).
4. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
5. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
6. Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113-1120 (2013).
7. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676-690 (2014).
8. Wilks, C. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Database 2014, bau093 (2014).
9. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
10. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
11. Solimini, N. L. et al. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science 337, 104-109 (2012).
12. Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17-37 (2013).
13. Dees, N. D. et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 22, 1589-1598 (2012).
14. Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
15. Tamborero, D. et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci. Rep. 3, 2650 (2013).
16. Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382-396 (2015).
17. Reimand, J. & Bader, G. D. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol. Syst. Biol. 9, 637 (2013).
18. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
19. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719-724 (2009).
20. Weinhold, N., Jacobsen, A., Schultz, N., Sander, C. & Lee, W. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat. Genet. 46, 1160-1165 (2014).
21. Meindl, A. et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 42, 410-414 (2010).
22. Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761-772 (2005).
23. Shih, C. & Weinberg, R. A. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29, 161-169 (1982).
24. Touw, I. P. & Erkeland, S. J. Retroviral insertion mutagenesis in mice as a comparative oncogenomics tool to identify disease genes in human leukemia. Mol. Ther. 15, 13-19 (2007).
25. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
26. Easton, D. F., Bishop, D. T., Ford, D. & Crockford, G. P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 52, 678-701 (1993).
27. Dittmer, D. et al. Gain of function mutations in p53. Nat. Genet. 4, 42-46 (1993).
28. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
29. Gonzalez-Perez, A. & Lopez-Bigas, N. Functional impact bias reveals cancer drivers. Nucleic Acids Res. 40, e169 (2012).
30. Tamborero, D., Gonzalez-Perez, A. & Lopez-Bigas, N. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics 29, 2238-2244 (2013).
31. Leiserson, M. D. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47, 106-114 (2015).
32. Vandin, F., Upfal, E. & Raphael, B. J. De novo discovery of mutated driver pathways in cancer. Genome Res. 22, 375-385 (2012).
33. Yoshihara, K. et al. The landscape and therapeutic relevance of cancerassociated transcript fusions. Oncogene 34, 4845-4854 (2014).
34. Forbes, S. A. et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652-D657 (2010).
35. UniProt, C. UniProt: a hub for protein information. Nucleic Acids Res. 43, D204-D212 (2015).
36. Pletscher-Frankild, S., Palleja, A., Tsafou, K., Binder, J. X. & Jensen, L. J. DISEASES: text mining and data integration of disease-gene associations. Methods 74, 83-89 (2015).
37. Huret, J. L. et al. Atlas of genetics and cytogenetics in oncology and haematology in 2013. Nucleic Acids Res. 41, D920-D924 (2013).
38. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739-1740 (2011).
39. Abbott, K. L. et al. The Candidate Cancer Gene Database: a database of cancer driver genes from forward genetic screens in mice. Nucleic Acids Res. 43, D844-D848 (2015).
40. Cowley, G. S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1, 140035 (2014).
41. Group, U. S. C. S. W. United States Cancer Statistics: 1999-2010 Incidence and Mortality Web-based Report. in cdc.gov (Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2014).
42. Vinagre, J. et al. Frequency of TERT promoter mutations in human cancers. Nat. Commun. 4, 2185 (2013).
43. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959 (2013).
44. Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489-494 (2015).
45. Simon, R. & Roychowdhury, S. Implementing personalized cancer genomics in clinical trials. Nat. Rev. Drug Discov. 12, 358-369 (2013).
46. Trudel, S. et al. The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma. BMC Cancer 14, 727 (2014).
47. Johung, K. L. et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J. Clin. Oncol. 34, 123-129 (2016).
48. Dietrich, S. et al. BRAF inhibition in refractory hairy-cell leukemia. N. Engl. J. Med. 366, 2038-2040 (2012).
49. McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra54 (2015).
50. Bolli, N. et al. A next generation sequencing-based approach to detect gene mutations, copy number changes and IGH translocations in multiple myeloma. Blood 124, 3364-3364 (2014).
51. Frampton, G. M. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023-1031 (2013).
52. Hovelson, D. H. et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia 17, 385-399 (2015).
53. Shao, D. D. et al. ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 23, 665-678 (2013).
54. Cohen, J. Statistical power analysis for the behavioral sciences. xxi, 567 p. (L. Erlbaum Associates, 1988).